Search This Blog

Wednesday, August 12, 2026

Sutro 'encouraging early Phase 1 data for STRO-004' after miss

 

Sutro Biopharma posts Q2 2026 loss with non-GAAP EPS -$2.33, revenue $9.8M, misses EPS and revenue estimates

  • Non-GAAP EPS of -$2.33 declined 66% YoY, while revenue of $9.8M fell 85% YoY.
  • Company also unveiled encouraging early Phase 1 data for STRO-004 alongside reporting Q2 2026 results.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)